TG003

• CAT Number: I004683
• CAS Number: 719277-26-6
• Molecular Formula: C13H15NO2S
• Molecular Weight: 249.33
• Purity: ≥95%
• Target: CIk1/CIk4
• Solubility: DMSO: ≥ 31 mg/mL
• Storage: 2-8°C
• IC50: 20 nM (Clk1); 15 nM(Clk4); 200 nM (CIk2) [1]
• IUPAC Name: (1Z)-1-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one
• InChI: InChI=1S/C13H15NO2S/c1-4-14-11-8-10(16-3)5-6-12(11)17-13(14)7-9(2)15/h5-8H,4H2,1-3H3/b13-7-
• InChIKey: BGVLELSCIHASRV-QPEQYQDCSA-N
• SMILES: CCN1C2=C(C=CC(=C2)OC)SC1=CC(=O)C

TG003（Cat No.:I004683） is a highly potent inhibitor of Clk1/Sty and Clk4, with IC50 values of 15-20 nM, making it a valuable tool for studying the functions of these kinases. However, it exhibits less potency against Clk2, with an IC50 value of 200 nM. By selectively targeting Clk1/Sty and Clk4, TG003 can help elucidate their roles in cellular processes and potentially serve as a therapeutic agent in diseases where these kinases are involved.

Reference

1:BMC Mol Biol. 2015 Sep 24;16:16. doi: 10.1186/s12867-015-0044-6. Deciphering targeting rules of splicing modulator compounds: case of TG003.Sakuma M,Iida K,Hagiwara M, PMID: 26400733 PMCID: PMC4580995 DOI: 10.1186/s12867-015-0044-6 Abstract: BACKGROUND: Recent advances in the development of small chemical compounds that can modulate RNA splicing brought excitement to the field of splicing-targeting therapy. Splicing-targeting therapy tries to ameliorate the disease by altering the exon combination of transcripts to reduce the undesired effect of genetic mutations. However, the knowledge and tools to understand factors contributing to splicing modulator compound sensitivity have been lacking. Our goal was to establish a method to characterize sequence features found in compound sensitive exons.RESULTS: Here we developed a comparative transcriptomic approach to explore features that make an exon sensitive to a chemical compound. In this study, we chose TG003, a potential drug for Duchenne muscular dystrophy, and performed RNA-sequencing on samples from human and mouse skeletal muscle cells, with and without TG003 treatments. We compared TG003 responsiveness between homologous exon pairs and identified 21 pairs in which human exons were skip-enhanced but not mouse exons. We compared the sequence features; splice site scores, number of splicing factor binding sites, and properties of branch sequence and polypyrimidine tracts, and found that polypyrimidine tracts were stronger (longer stretches and richer content of consecutive polypyrimidine) in the mouse TG003 insensitive exons. We also compared the features between TG003 skip-enhanced and insensitive exons within the species, and discovered that human TG003 skip-enhanced exons were shorter and had less splicing factor binding sites than the group of human TG003 insensitive exons. Mouse insensitive exons homologous to human TG003 skip-enhanced exons shared these properties. Our results suggested that these features are prerequisites for TG003 skip-enhanced exons and weak polypyrimidine tracts are defining features, which were supported by a decision tree analysis on all cassette exons in human.CONCLUSIONS: In this study we established a comparative transcriptomic approach, which shed lights on how small chemical compounds modulate RNA splicing. The results described here was the first attempt to decipher the targeting rules of a splicing modulator compound. We expect that this approach would contribute to the precise understanding of the mechanism of TG003-induced splicing modulation, expand target diseases of splicing modulators in general, as well as the development of new splicing modulators.